Table 1 Patient characteristics
From: Response to gefitinib and erlotinib in Non-small cell lung cancer: a retrospective study
| Gefitinib | Erlotinib | |||
|---|---|---|---|---|
| No | % | No | % | |
| TOTAL | 115 | 45 | ||
| Gender | ||||
| Female | 55 | 48 | 30 | 67 |
| Male | 60 | 52 | 15 | 33 |
| Age | ||||
| Avg. age | 66.53 | 66.76 | ||
| Range | 45-86 | 35-82 | ||
| Smoking history | ||||
| Smokers | 109 | 95 | 39 | 87 |
| Non-smokers | 5 | 1 | 4 | 9 |
| Unknown | 1 | 1 | 2 | 4 |
| Avg. pack-years | 43.6 | 42.2 | ||
| Histology | ||||
| Adenocarcinoma | 54 | 47 | 15 | 33 |
| Squamous | 27 | 23 | 9 | 20 |
| Bronchioalveolar | 8 | 6 | 2 | 4 |
| Large cell | 6 | 5 | 0 | 0 |
| Mixed | 2 | 2 | 0 | 0 |
| NSC not further specified | 17 | 15 | 20 | 44 |
| Avg. ECOG | 1.37 | 1.37 | ||
| Avg. previous lines of chemo | 1.26 | 1.13 | ||